Chest, Vol 92, 1032-1036, Copyright © 1987 by American College of Chest Physicians

ARTICLES

Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome [published erratum appears in Chest 1988 Aug;94(2):448]

RC Bone, CJ Fisher Jr, TP Clemmer, GJ Slotman and CA Metz
University of Arkansas for Medical Sciences, Little Rock.

From November 1, 1982 through December 31, 1985, there were 19 centers and 382 patients that evaluated the effect of methylprednisolone sodium succinate (MPSS) on the septic syndrome. Seventeen of these centers enrolled 304 patients in a prospective, randomized, double-blind, placebo-controlled study to determine if early treatment with MPSS would decrease the incidence of severity of the adult respiratory distress syndrome (ARDS) in patients at risk of ARDS from sepsis. To ensure early institution of the MPSS or placebo therapy (PLA), patients with the presumptive diagnosis of sepsis were identified. That diagnosis was based on the presence of fever or hypothermia (temperature greater than 38.3 degrees C or less than 35.5 degrees C, rectal), tachypnea (greater than 20 bpm), tachycardia (greater than 90 bpm) and the presence of one of the following indices of organ dysfunction: a change in mental status, hypoxemia, elevated lactate levels or oliguria. The treatment, either MPSS 30 mg/kg or PLA, was given in four 20-minute infusions six hours apart and was initiated within two hours of the presumptive diagnosis of sepsis. The development and reversal of the adult respiratory distress syndrome (ARDS) was followed and resulted in data on 304 of the 382 randomized patients. A trend toward increased incidence of ARDS was seen in the MPSS group 50/152 (32 percent) compared to the placebo group 38/152(25 percent) p = 0.10. Significantly fewer MPSS patients reversed their ARDS 15/50 (31 percent) compared to placebo 23/38 (61 percent) p = 0.005. The 14-day mortality in patients with ARDS treated with MPSS was 26/50 (52 percent) compared to placebo 8/22 (22 percent) p = 0.004. We conclude that early treatment of septic syndrome with MPSS does not prevent the development of ARDS. Additionally, MPSS treatment impedes the reversal of ARDS and increases the mortality rate in patients with ARDS.

This article has been cited by other articles:

				C. S. Calfee and M. A. Matthay Nonventilatory Treatments for Acute Lung Injury and ARDS Chest, March 1, 2007; 131(3): 913 - 920. [Abstract] [Full Text] [PDF]

				P. Marik, S. Pastores, D. Annane, R. Speich, C. Schmid, R. Stocker, H. Okamoto, M. J. DiNubile, K. P. Steinberg, L. D. Hudson, et al. Corticosteroids in ARDS. N. Engl. J. Med., July 20, 2006; 355(3): 316 - 317. [Full Text] [PDF]

				The National Heart, Lung, and Blood Institute Acut Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med., April 20, 2006; 354(16): 1671 - 1684. [Abstract] [Full Text] [PDF]

				G. R. Bernard Acute Respiratory Distress Syndrome: A Historical Perspective Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 798 - 806. [Abstract] [Full Text] [PDF]

				M. M. Levy, M. S. Baylor, G. R. Bernard, R. Fowler, T. J. Franks, F. G. Hayden, R. Helfand, S. E. Lapinsky, T. R. Martin, M. S. Niederman, et al. Clinical Issues and Research in Respiratory Failure from Severe Acute Respiratory Syndrome Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 518 - 526. [Abstract] [Full Text] [PDF]

				R. A. Balk Steroids for Septic Shock: Back From the Dead? (Pro) Chest, May 1, 2003; 123(5_suppl): 490S - 499S. [Abstract] [Full Text] [PDF]

				E. I. Majeski, R. A. Harley, S. C. Bellum, S. D. London, and L. London Differential Role for T Cells in the Development of Fibrotic Lesions Associated with Reovirus 1/L-Induced Bronchiolitis Obliterans Organizing Pneumonia versus Acute Respiratory Distress Syndrome Am. J. Respir. Cell Mol. Biol., February 1, 2003; 28(2): 208 - 217. [Abstract] [Full Text] [PDF]

				D. Johnson and I. Mayers Multiple organ dysfunction syndrome: a narrative review Can J Anesth, May 1, 2001; 48(5): 502 - 509. [Abstract] [Full Text] [PDF]

				D. J Lockey and A. R Manara The role of steroids following major trauma Trauma, January 1, 2001; 3(1): 53 - 61. [Abstract] [PDF]

				I. Mayers and D. Johnson Septic shock: treating more than just blood pressure Can. Med. Assoc. J., February 1, 2000; 162(3): 369 - 370. [Full Text] [PDF]

				S. HASHIMOTO, A. KOBAYASHI, K. KOOGUCHI, Y. KITAMURA, H. ONODERA, and H. NAKAJIMA Upregulation of Two Death Pathways of Perforin/Granzyme and FasL/Fas in Septic Acute Respiratory Distress Syndrome Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 237 - 243. [Abstract] [Full Text]

				M. A. JANTZ and S. A. SAHN Corticosteroids in Acute Respiratory Failure Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1079 - 1100. [Full Text]

				G. U. Meduri, A. S. Headley, E. Golden, S. J. Carson, R. A. Umberger, T. Kelso, and E. A. Tolley Effect of Prolonged Methylprednisolone Therapy in Unresolving Acute Respiratory Distress Syndrome: A Randomized Controlled Trial JAMA, July 8, 1998; 280(2): 159 - 165. [Abstract] [Full Text] [PDF]

				C. Brun-Buisson and L. Brochard Corticosteroid Therapy in Acute Respiratory Distress Syndrome: Better Late Than Never? JAMA, July 8, 1998; 280(2): 182 - 183. [Full Text] [PDF]

				M. H. Kollef and D. P. Schuster The Acute Respiratory Distress Syndrome N. Engl. J. Med., January 5, 1995; 332(1): 27 - 37. [Full Text] [PDF]